ProCE Banner Activity

Ibrutinib Plus Rituximab in Treatment-Naive Patients With Follicular Lymphoma

Slideset Download
Conference Coverage
Phase II data suggest that the chemotherapy-free regimen of ibrutinib plus rituximab is highly active in treatment-naive FL.

Released: December 10, 2015

Expiration: December 08, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen